Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
NCT00055055 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1056
Last updated 2026-05-06
Summary
This study will examine families in which one sibling of a sibling pair, or twin pair, has developed a systemic rheumatic disease and one has not, to see if and how the two differ in the following:
* Blood cell metabolism;
* Types of cells in the blood;
* Environmental exposures or genetic factors that might explain why one developed disease and the other did not.
Families in which one sibling has developed a systemic rheumatic disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, dermatomyositis, or myositis, and the other has not, are eligible for this study. The siblings may or may not be twins, but must be of the same gender and be within a 5-year age difference. Biological parents, or, in some cases, children, will also be included in the study. Normal, healthy volunteers will serve as control subjects.
Participants will undergo some or all of the following tests and procedures:
* Medical history and physical examination. Participants will also be asked permission to obtain medical records for review.
* Questionnaires about environmental exposures at work, at home, and elsewhere. Probands (participants with rheumatic disease) and their healthy siblings will also answer questions about infections, vaccinations, medications or dietary supplements, sun exposure, and stressful events during the year before disease diagnosis in the affected sibling.
* Blood and urine collection for the following tests:
* Routine blood chemistries and other studies to rule out certain diseases or medical problems;
* Evidence of past toxic exposures and certain infections;
* Presence of cells from the mother in the child s blood and vice versa. (Recent studies suggest that during pregnancy or delivery, cells from the mother and baby may be exchanged and circulate in the body for many years, possibly causing problems);
* In twin or sibling pairs, presence of certain genes that may be more common in patients with systematic rheumatic diseases as compared with their unaffected siblings and normal volunteers;
* In identical twins, comparison of their blood cell metabolism to see if and how the metabolism differs in people with rheumatic disease.
Participants may be asked for permission to have some of their blood and urine samples stored and to obtain previously collected blood or tissue biopsy specimens that are no longer needed for clinical care, for research purposes. They may also be asked to give additional blood or urine samples.
Participants will be followed every year for 5 years (either in person or by questionnaire) to evaluate any changes in their condition. The final 5-year evaluation will repeat some of the questionnaires and procedures described above.
Conditions
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Principal Investigators
-
Lisa G Rider, M.D. · National Institute of Environmental Health Sciences (NIEHS)
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-21
Countries
- United States
Study Locations
More Related Trials
-
The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
NCT00001375 ·Status: COMPLETED
-
Genetic Registry for Rheumatoid Arthritis
NCT00069472 ·Status: COMPLETED
-
Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients
NCT00001679 ·Status: COMPLETED
-
Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease
NCT02742337 ·Status: UNKNOWN
-
Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France
NCT02927535 ·Status: COMPLETED
-
Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis
NCT00321217 ·Status: UNKNOWN
-
Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis
NCT01111357 ·Status: COMPLETED
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502 ·Status: RECRUITING ·Phase: PHASE3
-
Prediction of Methotrexate Response - A Pilot Study
NCT01726959 ·Status: COMPLETED
-
Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in France
NCT02927509 ·Status: COMPLETED
-
Genetics and Mechanisms of Rheumatoid Arthritis
NCT01788098 ·Status: COMPLETED
-
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
NCT00902005 ·Status: COMPLETED
-
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00796705 ·Status: TERMINATED ·Phase: PHASE4
-
Relation of IL23R and IL17A Gene Polymorphisms Plus Serum Levels of IL23 and IL17A to Rheumatoid Arthritis Susceptibility and Activity
NCT05570513 ·Status: NOT_YET_RECRUITING
-
Empowering Physicians With Evidence-Based Decision Support for Pediatric Rheumatology
NCT02205086 ·Status: UNKNOWN ·Phase: NA
-
Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis
NCT05119452 ·Status: UNKNOWN ·Phase: NA
-
Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset
NCT05808309 ·Status: WITHDRAWN
-
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
NCT05576051 ·Status: COMPLETED
-
Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis
NCT02922192 ·Status: COMPLETED
-
Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors
NCT06177405 ·Status: COMPLETED
-
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis
NCT00579878 ·Status: COMPLETED ·Phase: PHASE3
-
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
NCT01981473 ·Status: COMPLETED
-
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850 ·Status: COMPLETED ·Phase: PHASE4
-
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
NCT05534347 ·Status: RECRUITING
-
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
NCT01328522 ·Status: COMPLETED ·Phase: PHASE1